July 6, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) hereby notifies the market that an application has been made to the London Stock Exchange and the UK Listing Authority for a total of 3,000,000 Ordinary Shares of 5 pence each fully paid (the “Shares”) to trade on the London Stock Exchange and to be admitted to the Official List. The Shares are to be reserved under a block listing pursuant to the Shire Portfolio Share Plan, the Shire Long Term Incentive Plan 2015 and the Shire Global Employee Stock Purchase Plan.
When issued, the Shares will rank equally with the existing issued Ordinary Shares of the Company.
Senior Assistant Company Secretary
|Ian Karpemail@example.com||+1 781 482 9018|
|Robert Coatesfirstname.lastname@example.org||+44 1256 894874|
|Lisa Adleremail@example.com||+1 617 588 8607|
|Debbi Fordfirstname.lastname@example.org||+1 617 949 9083|
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.